Piramal Pharma Solutions launches new microbiology laboratory at Lexington sterile injectable facility

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma, has opened a new microbiology laboratory at its sterile injectable facility in Lexington, Kentucky, US.

This addition marks a significant step forward in PPS' ongoing $85 million Lexington expansion, aimed at enhancing commercial-scale capabilities and improving operational efficiency. The new laboratory was released for routine GMP use on September 11, 2026, and shortly thereafter, its new sterility testing suite was conditionally approved, making the lab one of the first major components to come online in the expansion. The full manufacturing expansion is expected to be operational in late 2027.

The new lab more than triples the site's existing microbiology testing space, supporting improved laboratory workflow and providing additional capacity to accommodate future growth. The added space features three new biosafety cabinets, allowing PPS to run concurrent tests and reduce sample queue times. All incubators have also been consolidated within the new lab, further streamlining workflow and improving monitoring and accessibility across testing activities.